Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fennec Pharmaceuticals Inc. (FENC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under its Exchange Act reporting obligations. Fennec is a specialty pharmaceutical company focused on PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of cisplatin-induced ototoxicity in certain pediatric cancer patients.
Recent Form 8-K filings describe material definitive agreements and financing activities, such as an underwriting agreement for an underwritten registered public offering of common shares and subscription agreements for a non-brokered offering of common shares in Canada. These filings outline key terms of the offerings, the number of shares issued, the public offering price and the use of proceeds.
Other 8-K reports detail a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, under which Fennec agreed to repurchase and redeem its remaining senior secured floating rate convertible notes. The company reports that, after completing this transaction, all payment obligations under the notes were satisfied in full, and related news releases are incorporated by reference in the filings.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools can help readers quickly identify the purpose of each filing, such as equity offerings, debt redemptions or other corporate events, and understand how they relate to Fennec’s ongoing commercialization of PEDMARK® and its capital structure. Users can also track exhibits referenced in the 8-Ks, including underwriting agreements, subscription agreements, legal opinions and press releases.
Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss with its drug PEDMARK in the U.S. and PEDMARQSI in Europe and other regions. The product is FDA- and European Commission-approved for pediatric patients with localized, non-metastatic solid tumors and showed about a 50% relative reduction in hearing loss versus cisplatin alone in clinical studies.
In March 2024, Fennec signed an exclusive licensing deal with Norgine, receiving about $43 million upfront, with up to about $230 million in potential milestones and double-digit tiered royalties on PEDMARQSI net sales. Norgine launched PEDMARQSI in Germany and the U.K. in 2025, with further European launches expected. Fennec also added a 2025 distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries and reported positive 2025 Japanese STS-J01 trial results, supporting a registration strategy and potential partnering there.
The company has U.S. Orphan Drug Exclusivity for PEDMARK until September 20, 2029 and European pediatric-use marketing exclusivity until May 26, 2033, alongside a broad patent estate expiring around 2039. In March 2026, Fennec settled litigation with Cipla over a proposed generic, with Cipla agreeing not to launch its sodium thiosulfate product before September 1, 2033, reinforcing PEDMARK’s commercial runway.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.
Fennec Pharmaceuticals reported strong growth in its core PEDMARK product but a wider loss for 2025. Net product sales reached $44.6 million for the year, up 50% from 2024, with Q4 2025 net product sales of $13.8 million, 75% above Q4 2024. Total 2025 revenue was $44.6 million versus $47.5 million in 2024, which had included one-time licensing revenue. Operating expenses rose to $51.4 million, leading to a full-year net loss of $10.1 million compared with a $0.4 million net loss in 2024. Cash and cash equivalents increased to $36.8 million as of December 31, 2025, and all term-loan debt was eliminated, helping turn shareholders’ equity from a deficit to a positive $35.1 million. The company highlighted record patient enrollments and an oversubscribed $42 million equity raise, along with positive clinical data supporting PEDMARK’s use in additional settings.
Fennec Pharmaceuticals Inc. reported that it has entered into a License Agreement with Cipla Limited and Cipla USA, Inc. to settle litigation over Cipla’s bid to market a generic version of Fennec’s PEDMARK® sodium thiosulfate injection. The lawsuit will be dismissed, with each party bearing its own costs. Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances. PEDMARK, Fennec’s FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in certain pediatric cancer patients, remains the only approved product of its kind and is protected by orphan drug exclusivity and patents the company states extend to 2039.
Fennec Pharmaceuticals filed an 8-K to highlight a new clinical research collaboration with the Tampa General Hospital Cancer Institute. The institute is initiating a real-world study of PEDMARK (sodium thiosulfate injection) to evaluate its clinical utility in reducing cisplatin-related hearing loss in adolescent, young adult and adult cancer patients.
PEDMARK is already FDA-approved to reduce ototoxicity in pediatric patients 1 month and older with localized, non-metastatic solid tumors and carries a 2A recommendation from the National Comprehensive Cancer Network for adolescent and young adult use. The study will analyze real-world clinical data and audiology monitoring to help guide future clinical research and quality efforts in managing ototoxicity.
Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported multiple equity transactions. On March 2, 2026, he exercised 15,598 stock options at $2.45 per share, receiving the same number of common shares under a 10b5-1 plan adopted on September 19, 2025. He then sold 10,079 common shares at $8.36 per share to cover tax obligations linked to the option exercise. On February 28, 2026, he also acquired 5,208 common shares at no cost as previously awarded shares were released from restrictions. After these transactions, his direct common share holdings were 103,996 shares.
FENC Form 144 reports a proposed sale of 10,079 shares of Common Stock by Rostislav Raykov.
The filing also lists securities sold during the past three months: 10,349 shares on 02/02/2026 for $80,339.29, 10,312 shares on 01/02/2026 for $78,471.23, and 10,000 shares on 12/05/2025 for $75,444.00. The proposed sale is listed as a stock option exercise with a cash transaction.
Fennec Pharmaceuticals Inc. reported new real-world data on its drug PEDMARK® in adults with head and neck cancers. In a multi-institutional retrospective review of 15 adult patients, PEDMARK given at least six hours after cisplatin was feasible, well tolerated, and did not disrupt cisplatin-based treatment delivery.
Investigators observed early signals of hearing preservation, including that most high-risk patients receiving PEDMARK showed no measurable hearing loss during or after treatment, despite frequent baseline impairment. PEDMARK is currently approved in the United States only to reduce the risk of ototoxicity from cisplatin in pediatric patients with localized, non-metastatic solid tumors, and its safety and efficacy in adults with head and neck cancers have not been established.